• nanosensors that can profile tumors

    MIT researchers have designed nanosensors that can profile tumors and may yield insight into how they will respond to certain therapies. (Illustration: Christine Daniloff/MIT)

     

    Bhatia and Polina Anikeeva, the Class of 1942 Associate Professor of Materials Science and Engineering, are the senior authors of the paper, which appears in the journal Nano Letters (“Magnetically Actuated Protease Sensors for in Vivo Tumor Profiling”). The paper’s lead authors are Koch Institute postdoc Simone Schurle and graduate student Jaideep Dudani.Heat and release

    SOURCE

    September 2016

    Tumors, especially aggressive ones, often have elevated protease levels. These enzymes help tumors spread by cleaving proteins that compose the extracellular matrix, which normally surrounds cells and holds them in place.In 2014, Bhatia and colleagues reported using nanoparticles that interact with a type of protease known as matrix metalloproteinases (MMPs) to diagnose cancer. In that study, the researchers delivered nanoparticles carrying peptides, or short protein fragments, designed to be cleaved by the MMPs.

    If MMPs were present, hundreds of cleaved peptides would be excreted in the urine, where they could be detected with a simple paper test similar to a pregnancy test.In the new study, the researchers wanted to adapt the sensors so that they could report on the traits of tumors in a known location. To do that, they needed to ensure that the sensors were only producing a signal from the target organ, unaffected by background signals that might be produced in the bloodstream.

    They first designed sensors that could be activated with light once they reached their target. That required the use of ultraviolet light, however, which doesn’t penetrate very far into tissue.“We started thinking about what kinds of energy we might use that could penetrate further into the body,” says Bhatia, who is also a member of MIT’s Institute for Medical Engineering and Science.To achieve that, Bhatia teamed up with Anikeeva, who specializes in using magnetic fields to remotely activate materials.

    The researchers decided to encapsulate Bhatia’s protease-sensing nanoparticles along with magnetic particles that heat up when exposed to an alternating magnetic field. The field is produced by a small magnetic coil that changes polarity some half million times per second.The heat-sensitive material that encapsulates the particles disintegrates as the magnetic particles heat up, allowing the protease sensors to be released. However, the particles do not produce enough heat to damage nearby tissue.“It has been challenging to examine tumor-specific protease activities from patients’ biofluids because these proteases are also present in blood and other organs,” says Ji Ho (Joe) Park, an associate professor of bio and brain engineering at the Korea Advanced Institute of Science and Technology.

    “The strength of this work is the magnetothermally responsive protease nanosensors with spatiotemporal controllability,” says Park, who was not involved in the research. “With these nanosensors, the MIT researchers could assay protease activities involved more in tumor progression by reducing off-target activation significantly.”Choosing treatmentsIn a study of mice, the researchers showed that they could use these particles to correctly profile different types of colon tumors based on how much protease they produce.Cancer treatments based on proteases, now in clinical trials, consist of antibodies that target a tumor protein but have “veils” that prevent them from being activated before reaching the tumor.

    The veils are cleaved by proteases, so this therapy would be most effective for patients with high protease levels.The MIT team is also exploring using this type of sensor to image cancerous lesions that spread to the liver from other organs. Surgically removing such lesions works best if there are fewer than four, so measuring them could help doctors choose the best treatment.Bhatia says this type of sensor could be adapted to other tumors as well, because the magnetic field can penetrate deep into the body. This approach could also be expanded to make diagnoses based on detecting other kinds of enzymes, including those that cut sugar chains or lipids.

    Source: By Anne Trafton, MIT

    Read more: Nanosensors could help determine tumors’ ability to remodel tissue

     
     

    No comments

    Be the first one to leave a comment.

    Post a Comment


     

     

    Latest Posts

    Latest Video

     
     

    LATEST POSTS

    Chinese surgeons use 3D printing in two landmark paediatric heart surgeries

     SOURCE Chinese surgeons have utilised 3D printing technology to perform two different paediatric heart surgeries. The surgeries took place at the Second Xiangya Hospital of Central…

    How Apps are Changing the Medical Field

      Our last article about Catalia Health and the company’s use of social robots to provide a better healthcare experience to patients created a huge…

    IBM Watson finding its way into real-world image interpretation

    Posted by admin / January 23, 2017 / Edit post Photo: Twitter user Deborah DiSanzo SOURCE A large radiology practice in the Miami area is…

    IBM uses Smartphone to to help Diagnose Melanoma

    SOURCE The smartphone is on a collision course with your local dermatologist. IBM researchers have developed a computer system that early research shows is more…

    Engineers Have Created Biocompatible Microrobots That Can be Implanted Into the Human Body

    SOURCE  Sam Sia, a Biomedical Engineering Professor at Columbia Engineering recently led a team that used biomaterials that can safely be implanted in the body…

    First FDA Approval For Clinical Cloud-Based Deep Learning In Healthcare

     SOURCE: FORBES The first FDA approval for a machine learning application to be used in a clinical setting is a big step forward for AI…

    FDA-approved study uses adipose stem cells for treatment of shoulder injuries

    SOURCE Sanford Health is conducting the first clinical trial approved by the FDA to treat injured shoulders using patients’ adipose stem cells. “A number of…

    Could Anatomics BioModel Stereotaxy replace navigation or a robot?

    SOURCE Paul S D’Urso Neurosurgeon & Founder of Anatomics Because 3D printing is so accurate I was able to locate targets within .5 mm accuracy. Patient…